Drug metabolizing enzymes

Current Opinion in Critical Care

Volumn 4, Issue 4, 1998, Pages 213-218

  Maurel, Patrick ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001415920     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-199808000-00001     Document Type: Article

References (74)

1. Parkinson A: Biotransformation of xenobiotics. In Casarett & Doull's Toxicology: The Basic Science of Poisons. Edited by Klaassen CD. New York: McGraw-Hill Health Profession Division; 1996:113-186. An excellent and extensive review of drug metabolizing enzymes including systems of phase I and phase II.
2. Jakoby WB: Enzymatic Basis of Detoxication; VoI I, II. New York: Academic Press; 1980.
3. Maurel P: The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Deliv Rev 1996, 22:105-132. A review on the use of in vitro systems including human hepatocytes in primary culture to investigate drug metabolism under conditions where direct evaluation in man is not possible for ethical reasons.
4. Gonzalez FJ: The molecular biology of cytochrome P450s. Pharmacol Rev 1989, 40:243-288.
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42. A review on CYP superfamily nomenclature.
6. Kalow W: Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991, 12:102-107.
7. Gonzalez FJ: Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992, 13:346-352.
8. Cholerton S, Daly AK, Idle JR: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992, 13:434-439.
9. Coon MJ, Xinxin D, Pernecky SJ, Vaz ADN: Cytochrome P450: progress and predictions. FASEB J 1992, 6:669-673.
10. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP: Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation: two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985, 260:9057-9067.
11. Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988, 26:363-372.
12. Guengerich FP: Characterization of roles of human cytochrome P-450 enzymes in carcinogen metabolism. Asia Pac J Pharmacol 1990, 5:327-345.
13. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel P: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990, 99:737-747.
14. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, Maurel P: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994, 269:384-392.
15. Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I: Increase of cytochrome P450 1A2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992, 52:170-180.
16. McDonnell WM, Scheiman JM, Traber PG: Induction of cytochrome P450 1A genes (CYP1) by omeprazole in the human alimentary tract. Gastroenterology 1992, 103:1509-1516.
17. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993, 36:521-530.
18. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR: Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990, 267:365-371.
19. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J, Lange R: Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 1991, 200:511-517.
20. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T: Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 1993, 21:1048-1056.
21. Dalet-Beluche I, Boulenc X, Fabre G, Maurel P, Bonfils C: Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. Eur J Biochem 1992, 204:641-648.
22. Chang TKH, Yu L, Maurel P, Waxman DJ: Enhanced activation of cyclophosphamide and ifosphamide in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997, 57:1946-1954.
23. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinkiri N, Lloyd RS, Guengerich FP: Characterization of cDNAs, mRNA, and proteins related to human liver microsomal cytochrome P450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988, 27:6929-6940.
24. Wrighton SA, Stevens JC, Becker GW, Vandenbranden M: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C1 9 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993, 306:240-245.
25. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994, 33:1743-1752.
26. Morel F, Beaune P, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A: Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 1990, 191:437-444.
27. Goldstein JA, de Morais MF: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994, 4:285-299.
28. Inoue K, Yamasaki H, Imiya K, Akasaka S, Guengerich PF, Shimada T: Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997, 7:103-114.
29. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zang ZY, Kaminski LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in tolbutamide polymorphism. Pharmacogenetics 1996, 6:341-349.
30. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ: The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989, 45:889-904.
31. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988, 331:442-446.
32. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JO, Idle JR, Ingelman-Sundberg M, Ishizaki E, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996, 6:193-202. A review on CYP2D6 mutant alleles nomenclature and features.
33. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, Albano E: Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993, 10:447-452.
34. Koop DR: Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992, 6:724-730.
35. Perrot N, Nalpas B, Yang CS, Beaune PH: Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake. Eur J Clin Invest 1989, 19:549-555.
36. Eliasson E, Mkrtchian S, Ingelman-Sundberg M: Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem 1992, 267:15765-15769.
37. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I: Human cytochrome P4502E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996, 6:203-211.
38. Maurel P: The CYP3A family. In Cytochromes P450: Metabolic and Toxicological Aspects. Edited by loannides C. Boca Raton: CRC Press; 1996:241-270.
39. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992, 90:1871-1878.
40. Lown KS, Kolars JC, Thummel, KE, Barnett JL, Kunze KL, Wrighton SA. Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994, 22:947-955.
41. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P: The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 1989, 28:373-387.
42. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G. Maurel P: Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990, 18:595-606.
43. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986, 261:5051-5060.
44. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ: Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroids and cyclosporine. J Biol Chem 1989, 264:10388-10395.
45. Schuetz JD, Beach DL, Guzelian PS: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994, 4:11-20,
46. Jounaidi Y, Hyrailles V, Gervot L, Maurel P: Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 1996, 221:466-470.
47. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M: Studies on the expression and metabolic capability of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990, 38:207-213.
48. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991, 290:160-166.
49. Komori M, Nishio K, Ohi H, Kitada M, Kamataki T: Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P450. J Biochem (Tokyo) 1989, 105:161-163.
50. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, Nagashima K, Kamataki T: Fetus-specific expression of a form of cytochrome P450 in human liver. Biochemistry 1990, 29:4430-4433.
51. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth GF, Raucy J, Guzelian P, Gionela K, Watlington CO: Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 1992, 294:206-214.
52. Greuet J, Pichard L, Bonfils C, Domergue J, Maurel P: The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochem Biophys Res Commun 1996, 225:689-694.
53. Schuetz JD, Kauma S, Guzelian PS: Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993, 92:1018-1024.
54. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ: The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Medicine 1998, 4:92-96. A paper reporting on the discovery that rifampicin, a potent inducer of CYP3A4 in humans, is able to bind and activate the human glucocorticoid receptor. An editorial by Blanchard on this paper (News and Views, Nat Med 1998, 4:14-15) discusses the impact of this discovery on the explanation of other possible pharmacologic effects of rifampicin.
55. Kliewer SA, Moore JT, Wade, L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Wilson TM, Zetterström RH, et al. An ophan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92:1-20. An excellent paper reporting on the discovery and characterization of a new rat nuclear receptor that may be activated by pregnanes, some of them being inducers of CYP3As.
56. Park GR, Pichard L, Tinel M, Larroque C, Elston A, Domergue J, Dexonne B, Maurel P: What changes drug metabolism in critically ill patients? Two preliminary studies in isolated human hepatocytes. Anesthesia 1994, 49:188-191.
57. Shan X, Aw TY, Smith ER, Ingelman-Sundberg M, Mannervik B, lyanagi T, Jones DP: Effect of chronic hypoxia on detoxification enzymnes in rat liver. Biochem Pharmacol 1992, 43:2421-2426.
58. Proulx M, du Souich P: Acute moderate hypoxia in conscious rabbits: effect on hepatic cytochrome P450 and on reactive oxygen species. J Pharm Pharmacol 1995, 47:392-397.
59. Henrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
60. Akira S, Hirano T, Taga T, Kishimoto T: Biology of multifunctional cytokmes: IL 6 and related molecules. (IL 1 and TNF). FASEB J 1990, 4:2860-2867.
61. Fey GH, Hocke GM, Wilson DR, Ripperger JA, Juan TSC, Cui MZ, Darlington GJ: Cytokines and the acute phase response of the liver. In The Liver: Biology and Patholgy, edn. 3. Edited by Arias IM, Boyer JL, Fausto N, Jacoby WB, Schachter DA, Shafritz. New York: Raven Press; 1994:113-143.
62. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P: Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995, 22:1143-1153.
63. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993, 44:707-715.
64. Peterson TC Renton KW: Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450. Biochem Pharmacol 1986, 35:1491-1497.
65. Morgan ET: Suppression of constitutive cytochrome P450 gene expression in liver of rats undergoing an acute phase response to endotoxin. Mol Pharmacol 1989, 36:699-707.
66. Poüs C, Giroud JP, Damais D. Raichvarg D, Chauvelot-Moachon L: Effect of recombinant human interleukin-1 β and tumor necrosis factor α on liver cytochrome P450 and serum α-1-acid glycoprotein concentration in the rat. Drug Metab Dispos 1990, 18:467-470.
67. Wright K, Morgan ET: Regulation of cytochrome P450IIC12 expression by interleukin-1 a, interleukin-6, and dexamethasone. Mol Pharmacol 1991, 39:468-474.
68. Barker CW, Fagan JB, Pasco DS: Interleukin-1β suppresses the induction of P4501A1 and P4501A2 mRNA in isolated hepatocytes. J Biol Chem 1992, 267:8050-8055.
69. Moochhala SM: Alteration of drug biotransformation by interferon and host defence mechanism. Ann Acad Med 1991, 20:13-18.
70. Shiota G, Okano JI, Kawasaki H, Kawamoto T, Nakamura T: Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995, 21:106-112.
71. Jean Marie I, Dalet C, Blanchard JM, Astre C, Szawlowski A, Saint Aubert B, Joyeux H, Maurel P: Inhibition of cytochrome P-450p (P450IIIA1) gene expression during liver regeneration from two-thirds hepatectomy in the rat. Biochem Pharmacol 1988, 37:3515-3521.
72. Liddle C, Murray M, Farrell GC: Effect of liver regeneration on hepatic cytochrome P450 isozymes and serum sex steroids in the male rat. Gastroenterology 1989, 96:864-872.
73. Blanc P, Etienne H, Daujat M, Fabre I, Zindy F, Domergue J, Astre C, Saint Aubert B, Michel H, Maurel P: Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor a, and human serum. Gastroenterology 1992, 102:1340-1350.
74. Greuet J, Pichard L, Ourlin JC, Bonfils C, Domergue J, Le Treut P, Maurel P: Effect of cell density and epidermal growth facotr on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture. Hepatology 1997, 25:1166-1175.